EASL Clinical Practice Guidelines: management of hepatitis C virus infection

European Association for Study of Liver, David Mutimer, Alessio Aghemo, Helmut Diepolder, Francesco Negro, Geert Robaeys, Stephen Ryder, Fabien Zoulim, European Association for Study of Liver, David Mutimer, Alessio Aghemo, Helmut Diepolder, Francesco Negro, Geert Robaeys, Stephen Ryder, Fabien Zoulim

No abstract available

Keywords: AE; ALT; BMI; BOC; BT; CPGs; CYP3A4; Clinical Practice Guidelines; DAA; DVR; EIA; EPO; EVR; G-CSF; GRADE; Grading of Recommendations Assessment, Development and Evaluation; HBV; HCC; HCV; IDU; IFN; IU; LSM; LT; OST; PI; PWID; PegIFN/RBV; RVR; SCAR; SVR; TSH; TVR; adverse event; alanine aminotransferase; boceprevir; body mass index; cytochrome p450 3A4; delayed virological response; direct-acting antiviral; eRVR; early virological response; enzyme immunoassays; erythropoietin; extended rapid virological response; granulocyte colony stimulating factor; hepatitis B virus; hepatitis C virus; hepatocellular carcinoma; interferon; international units; intravenous/injecting drug use; liver stiffness measurement; liver transplant; opiate/opioid substitution treatment/therapy; pegylated interferon-α and ribavirin; people who inject drugs; protease inhibitor; rapid virological response; severe cutaneous adverse reaction; sustained virological response; telaprevir; thyroid stimulating hormone; viral breakthrough.